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Abstract
Background: Streptolysin S (SLS) is a cytolytic virulence factor produced by the human pathogen Streptococcus
pyogenes and other Streptococcus species. Related “SLS-like” toxins have been characterized in select strains of
Clostridium and Listeria, with homologous clusters bioinformatically identified in a variety of other species. SLS is a
member of the thiazole/oxazole-modified microcin (TOMM) family of natural products. The structure of SLS has yet
to be deciphered and many questions remain regarding its structure-activity relationships.
Results: In this work, we assessed the hemolytic activity of a series of C-terminally truncated SLS peptides expressed
in SLS-deficient S. pyogenes. Our data indicate that while the N-terminal poly-heterocyclizable (NPH) region of SLS
substantially contributes to its bioactivity, the variable C-terminal region of the toxin is largely dispensable. Through
genome mining we identified additional SLS-like clusters in diverse Firmicutes, Spirochaetes and Actinobacteria.
Among the Spirochaete clusters, naturally truncated SLS-like precursors were found in the genomes of three Lyme
disease-causing Borrelia burgdorferi sensu lato (Bbsl) strains. Although unable to restore hemolysis in SLS-deficient S.
pyogenes, a Bbsl SLS-like precursor peptide was converted to a cytolysin using purified SLS biosynthetic enzymes. A
PCR-based screen demonstrated that SLS-like clusters are substantially more prevalent in Bbsl than inferred from
publicly available genome sequences.
Conclusions: The mutagenesis data described herein indicate that the minimal cytolytic unit of SLS encompasses
the NPH region of the core peptide. Interestingly, this region is found in all characterized TOMM cytolysins, as well
as the novel putative TOMM cytolysins we discovered. We propose that this conserved region represents the
defining feature of the SLS-like TOMM family. We demonstrate the cytolytic potential of a Bbsl SLS-like precursor
peptide, which has a core region of similar length to the SLS minimal cytolytic unit, when modified with purified
SLS biosynthetic enzymes. As such, we speculate that some Borrelia have the potential to produce a TOMM
cytolysin, although the biological significance of this finding remains to be determined. In addition to providing new
insight into the structure-activity relationships of SLS, this study greatly expands the cytolysin group of TOMMs.
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Background
Streptococcus pyogenes (Group A Streptococcus) com-
monly causes mild diseases such as pharyngitis and im-
petigo, and in rare cases, invasive infections such as
necrotizing fasciitis and streptococcal toxic shock syn-
drome [1]. While the characteristic β-hemolytic pheno-
type of S. pyogenes grown on blood agar has long been
known [2], more than four decades passed before the re-
sponsible hemolytic/cytolytic factor was identified [3],
streptolysin S (SLS) [4]. The eventual discovery of the
SLS biosynthetic gene cluster [5] prompted investiga-
tions that subsequently designated SLS a member of the
thiazole/oxazole-modified microcin (TOMM) group of
natural products [6–8]. TOMMs are a class of function-
ally and structurally diverse ribosomal peptides that are
posttranslationally modified to contain the eponymous
thiazole and (methyl)oxazole heterocycles derived from
select cysteine, serine, and threonine residues [8]. The
SLS biosynthetic operon (Fig. 1a) encodes a precursor
peptide, SagA (Fig. 1b), and three heterocycle-forming
proteins, SagBCD [5, 7]. Similar to other characterized
ribosomal natural products, the SagA N-terminal leader
peptide contains residues recognized by the modifying
enzymes, while the C-terminal core peptide undergoes
heterocyclization [7, 9, 10] (Fig. 1b and c). The suspected
protease, SagE, is believed to remove the leader peptide
[11, 12], permitting the export of mature and bioactive
SLS via a dedicated ABC transporter, SagGHI (Fig. 1a).
SLS is the founding member of a group of homolo-
gous TOMM cytolysins that have been characterized
in other Streptococcus species (Additional file 1: Figure
S1A), including invasive human isolates of the β-
hemolytic Group C and Group G streptococci, which
belong to S. dysgalactiae subsp. equisimilis [13]. SLS
variants are also produced by the animal pathogens S.
iniae [14] and S. equi [15]. More recently, S. anginosus,
a human commensal organism and emerging oppor-
tunistic pathogen, has been shown to produce twin
SLS homologs [16]. Notably, SLS-like toxins are not lim-
ited to Streptococcus, being produced by other Firmicutes
including select strains of Clostridium [17] and Listeria




Fig. 1 Gene cluster organization and precursor peptide sequences of SLS-like cytolysins, and post-translational modification scheme. a Lettering
corresponds to the SLS operon “sag” genes. The proposed function of each gene is color-coded according to the legend. A representative is
shown, as in some cases, organization varies among strains and/or not all strains of a species possess the cluster. b Heterocyclizable residues
(Cys, Ser, Thr) are shown in blue. The predicted leader cleavage sites are indicated with carets. abioactivity of “clostridiolysin S” shown from C. spor-
ogenes [17] and upon heterologous expression in S. pyogenes ΔsagA [7] bbioactivity of “listeriolysin S” shown from native producers [19, 18], but
neither the precursor peptide nor core peptide fused to SagA leader were cytolytic upon heterologous expression in S. pyogenes ΔsagA [7].
cbioactivity of putative cytolysin not yet shown from a native producer, but core peptide fused to SagA leader cytolytic upon heterologous
expression in S. pyogenes ΔsagA [7]. c Azole heterocycles are installed on a TOMM precursor peptide by the successive action of a cyclodehydratase
(C and D proteins) and dehydrogenase (B protein). X = S or O; R = H or CH3
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Despite intense study, the precise mechanism of SLS
toxicity towards mammalian cells remains incompletely
understood [21]. SLS has also thus far been recalcitrant
to structural elucidation owing to its poor physicochemi-
cal properties, although an extensive mass spectral ana-
lysis detected two oxazole moieties at positions S46 and
S48 of SLS modified with purified biosynthetic enzymes
[17] (Fig. 2a). Previous mutagenesis studies indicate that
residues spanning the entire SLS core peptide are re-
quired for S. pyogenes hemolysis [7, 22] (Additional file
1: Figure S1B). This contrasts with the highly conserved
N-terminal poly-heterocyclizable (NPH) region and vari-
able C-terminus of SLS natural variants (Additional file 1:
Figure S1A). Here, we sought to reconcile these discrepan-
cies by probing the contribution of the C-terminus to SLS
bioactivity. We demonstrate that severely C-terminally
truncated SLS peptides expressed in a sagA deletion mu-
tant of S. pyogenes M1 5448 (S. pyogenes ΔsagA) retain
hemolytic activity and posit that the NPH region found in
all TOMM cytolysins is the defining feature of the family
(Fig. 2a, underlined portion). Using bioinformatics, we
identified a set of SagA homologs containing the NPH re-
gion in TOMM biosynthetic clusters in additional Firmi-
cutes, as well as the Actinobacteria and Spirochaete phyla.
We demonstrate that a naturally truncated precursor pep-
tide encoded by a member of Borrelia burgdorferi sensu
lato (Bbsl) species group can be matured into a cytolysin
using purified SLS biosynthetic enzymes. Notably, several
Bbsl cause Lyme disease, the most commonly reported
tick-borne illness in the Northern hemisphere [23, 24],
and our PCR-based screen revealed that genes encoding
SLS-like precursors are prevalent in diverse Bbsl isolates.
While our preliminary findings are intriguing, it remains
to be seen if these putative cytolytic TOMMs are pro-
duced by Borrelia, and if so, whether they function to en-
hance virulence. Together, our results identify the minimal
cytoytic determinant of SLS and indicate that there are po-
tentially considerably more producers of related cytolysins
than currently appreciated.
Results and discussion
Expression of truncated SLS precursors in S. pyogenes
ΔsagA reveals the importance of N-terminal heterocyclizable
region for hemolytic activity
An alignment of experimentally validated SLS core pep-
tides revealed a highly conserved N-terminal region, con-
taining 9–10 contiguous heterocyclizable residues, while
the C-terminus is considerably more variable in terms
of both identity of residues and length (Additional file
1: Figure S1A). Since only the NPH region of the core
peptide is apparently under strict evolutionary pressure,
we postulated that the C-terminal region might be less
important for SLS function. Indeed, heterologous ex-
pression data support this, as peptides with divergent
C-termini were able to restore the β-hemolytic pheno-
type in S. pyogenes ΔsagA [7] (Fig. 1b). To test our hy-
pothesis, we installed premature stop codons in sagA
(Fig. 2a) and expressed the resultant C-terminally trun-
cated SLS derivatives in S. pyogenes ΔsagA. Unfortu-
nately, the ring-state of processed SagA cannot be
A
B
Fig. 2 Assessment of the hemolytic activity of truncated SLS precursor peptides expressed in S. pyogenes ΔsagA. a Residues of the SagA core
peptide are numbered. Potentially modified residues of SLS are blue, while those known to be heterocyclized when SagA is modified with
purified SagBCD are purple. The predicted leader cleavage site is indicated with a caret. The positions of stop codons introduced in SagA are
marked with asterisks (yields truncation mutants listed in panel B). The minimal core region required for hemolytic activity of SLS in S. pyogenes
ΔsagA (SagA24–34) is underlined (see panel B). b The labels correspond to the SagA truncation mutants described in panel A. A representative
colony on blood agar of GAS M1 ΔsagA expressing each precursor from pDCerm is shown. The colony labeled “Empty” was a negative control
containing pDCerm vector
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readily determined, even with advanced spectroscopic
methods [17, 6]. We thus relied on a simple phenotypic
assay, i.e. β-hemolysis on blood agar, to simultaneously
evaluate successful production and export of SLS
derivatives.
Consistent with the divergence of the core peptides
(Additional file 1: Figure S1A), SLS retained significant
activity upon C-terminal truncation. In fact, S. pyogenes
ΔsagA expressing SLS derivatives missing up to 17 resi-
dues (SagA1–36) showed comparable levels of β-hemolysis
on blood agar to that complimented with full-length SagA
(Fig. 2b). Hemolytic activity substantially decreased with
additional truncation to yield SagA1–35 and SagA1–34, with
activity being undetectable in the case of SagA1–33
(Fig. 2b). These findings allowed us to define SagA24–34 as
the minimal unit required for hemolytic activity of SLS
expressed by S. pyogenes, assuming leader cleavage at the
predicted site (Fig. 2a). Interestingly, this segment encom-
passes the entirety of the conserved NPH region (Add-
itional file 1: Figure S1A), as well as just two additional
residues (Fig. 2a). Based on the predicted leader peptide
cleavage site [22], this indicates that only 11 core residues
are required for detectable bioactivity of SLS expressed by
S. pyogenes.
The retention of activity by such drastically C-terminally
truncated SLS derivatives expressed in S. pyogenes ΔsagA
stands in contrast to alanine substitution studies that im-
plicated several of the “missing” residues in SLS activity by
both expression in S. pyogenes ΔsagA and by modification
using purified enzymes (Additional file 1: Figure S1B) [7,
22]. While a K53A mutation eliminated SLS hemolytic ac-
tivity from S. pyogenes [22], our truncation series demon-
strated that its removal is not detrimental to activity
(Fig. 2b). Our results are consistent with the existence of
natural SLS variants that lack a terminal lysine (Additional
file 1: Figure S1A). Moreover, known SLS-like toxins
encoded by non-Streptococcus species also lack terminal
lysines (Fig. 1b). Even more striking is our observation that
peptides that lack S39 retain cytolytic activity (Fig. 2b).
S39 was identified as a critical residue because S. pyo-
genes ΔsagA expressing SagA-S39A was devoid of cyto-
lytic activity and avirulent in a mouse infection model
[7] (Additional file 1: Figure S1B). As before, this pos-
ition is not conserved in the SLS family (Additional file
1: Figure S1A) or in SLS-like toxins encoded by non-
Streptococcus species (Fig. 1b). Finally, many of our
mutants that lack the unconserved residues S46 and
S48 are hemolytic to levels indistinguishable from WT.
Previous mutagenesis suggested that these positions
contribute to the hemolytic properties of SLS both in S.
pyogenes and when modified with purified enzymes [7].
S46 and S48 have also been shown to be cyclized when
SLS is modified with its cognate purified biosynthetic
enzymes [17], although it is not known if this holds
true for native SLS. Thus, many positions that were
previously implicated in SLS activity by point mutation
are not conserved across the SLS family and were
herein found to be dispensable. In the absence of a
complete structure for SLS or detailed mechanism of
action, it is unclear why mutation of a residue can be
more detrimental than removal, but it is possible that
the “alanine-substituted” toxins adopt an unproductive
topology that is incapable of lysing cells.
Bioinformatics-guided discovery of novel TOMM
cytolysins
Given that the number of bioinformatically identifiable
TOMM biosynthetic clusters more than quadrupled
since 2011 [8, 25], we sought to determine if naturally
truncated precursor peptides are present in any novel
SLS-like clusters. Our genome mining effort revealed
TOMM clusters encoding SagB, −C and –D homologs
in the vicinity of SagA homologs in Firmicutes genera not
previously known to possess such clusters (i.e. Bacillus,
Lactobacillus, Enterococcus, Exiguobacterium, Oenococcus
and Virgibacillus) (Additional file 2: Figure S2A and
Additional file 3: Table S1). Interestingly, a number of
Actinobacteria (Mobiluncus and Propionibacterium) and
Spirochaetes (Borrelia and Brachyspira) encode SLS-like
clusters (Additional file 2: Figure S2A and Additional
file 3: Table S1). The Brachyspira TOMM clusters were
independently noted in a recent publication [26]. We
hypothesized that the newly-annotated SLS-like precur-
sors (Additional file 2: Figure S2B) represent novel
TOMM cytolysins since the sequence of a TOMM pre-
cursor dictates the function of the natural product after
posttranslational modification [8, 6]. Moreover, while
the novel SagA-like precursor peptides were of variable
length, all contained the aforementioned NPH region.
Our identification of these putative SLS-like cytolysins
greatly expands the TOMM cytolysin family (Fig. 3 and
Additional file 4: Table S2) and suggests that the
TOMM cytolysins are not confined to Firmicutes.
Of particular interest were the three potential SLS-like
TOMM biosynthetic clusters we discovered among the
23 published Bbsl genomes (Fig. 4a; hereafter referred to
as “Bor TOMM clusters”), namely in B. afzelii PKo
[GenBank: CP002947] [27], B. valaisiana VS116 [Gen-
Bank: CP001442] [28] and B. spielmanii A14S [Gen-
Bank: CP001465] [28]. The novel Bbsl-encoded
precursor peptides were SagA homologs with core re-
gions of similar length to our “minimal cytolytic unit”
for SLS (Fig. 4b). We preliminarily classified the putative
Bbsl SLS-like products as TOMM cytolysins based on
sequence similarity to SLS, with support from a max-
imum likelihood tree of a subset of the TOMM family
based on the associated D proteins (Fig. 4c). Thus, we
assigned names to the homologous genes within the
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clusters following the SLS nomenclature, with borA en-
coding the precursor peptide (refers collectively to bafzA
from B. afzelii PKo, bvalA from B. valaisiana VS116,
and bspiA from B. spielmanii A14S; Fig. 4b), borB en-
coding the dehydrogenase and borC/D encoding the
cyclodehydratase and so forth.
SLS-like TOMM biosynthetic genes are widely distributed
among Bbsl
We noted that the Bor TOMM clusters identified in B.
afzelii PKo, B. valaisiana VS116 and B. spielmanii
A14S were present on lp28-8 plasmids (Additional file 5:
Figure S3). These plasmids exhibit 7-9 % nucleotide se-
quence divergence from each other, which is consistent
with that observed on the chromosome and other linear
plasmids in these species [29]. Moreover, the G + C con-
tent of the cluster is 25-26 % in all three species, which is
typical for Bbsl plasmids. It thus appears that the Bor
TOMM cluster did not arrive into the genus recently by
horizontal transfer, but has likely been present for a long
time, diverging in parallel with the chromosome approxi-
mately when the three species diverged.
We hypothesized that the three Bor TOMM clusters
identified in Bbsl genomes are an underestimation of the
true prevalence given that Bbsl are prone to losing plas-
mids when cultured in vitro [30, 31]. In order to esti-
mate the distribution of Bor TOMM clusters in Bbsl, we
performed a PCR screen for the associated biosynthetic
Fig. 3 Phylogenetic analysis of the TOMM cytolysin family. A maximum-likelihood tree based on the D protein (listed in Additional file 4: Table S2) for
the majority of known and putative producers of cytolytic TOMMs (as of December 2014). This phylogenetic data is deposited in the Dryad Digital
Repository, doi:10.5061/dryad.d4863. Clades are color-coded based on the originating genus for each SLS-like toxin, as represented in the legend. The
relevant phyla are given in parentheses
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genes in 140 genomic DNA samples from tick or human
patient isolates (Additional file 6: Table S3). Seven Bbsl
species were represented, originating from North America
and 13 countries in Europe and Asia. Because of the similar-
ity among the VS116, PKo, and A14S Bor TOMM cluster
sequences, primers specific to bvalB, -C and -D were used
to detect borB, -C and -D in the isolates (Additional file 7:
Figure S4 and Additional file 8: Table S4).
Our results reveal that Bor TOMM biosynthetic genes
are present in select B. afzelii, B. spielmanii, B. valaisiana,
B. lusitaniae, and B. garinii isolates (Additional file 6:
Table S3, summarized in Table 1). In line with the well-
known plasmid instability of Borrelia plasmids, we ob-
served cases of passage-dependent amplification of Bor
TOMM genes (Additional file 6: Table S3). While all three
biosynthetic genes could be amplified from some of the
aforementioned strains, there were many instances where
only one or two biosynthetic genes were detected (Table 1
and Additional file 6: Table S3). Overall, borC was success-
fully amplified more frequently than borB or borD, likely
due to higher conservation at the extreme 5′ and 3′ ends
where the primers were designed to anneal (Additional file
7: Figure S4). Since mutational inactivation of nonessential
genes is quite common on Bbsl linear plasmids, another
possibility is that some target genes are too divergent to
detect with the primers employed [32].
In contrast, Bor TOMM genes were absent from all




Fig. 4 Gene cluster organization and precursor peptide sequences of SLS and Bor TOMM, and phylogenetic analysis of the TOMM family. a Lettering
corresponds to the SLS operon “sag” genes. The proposed function of each gene is color-coded according to the legend. b BorA refers collectively to
BafzA from B. afzelii PKo, BvalA from B. valaisiana VS116, and BspiA from B. spielmanii A14S. Potentially modified residues are shown in blue.
The predicted leader cleavage sites are indicated with a caret. The minimal core region required for hemolytic activity of SLS in S. pyogenes
ΔsagA (SagA24–34) is underlined. c A maximum-likelihood tree of a representative sample of TOMMs based on the D protein from each cluster.
This phylogenetic data is deposited in the Dryad Digital Repository, doi:10.5061/dryad.d4863. Clades are color-coded based on the predicted
class of TOMM natural product. NHLP, nitrile hydratase leader peptide; NHLP-Burk, NHLP from Burkholderia; PZN, plantazolicin; Balh, uncharacterized
TOMM from Bacillus sp. Al Hakam; McB, microcin B from Gammaproteobacteria; SLS, streptolysin S; Bor TOMM, putative SLS-like cytolysin from Bbsl
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isolates screened (Table 1 and Additional file 6: Table
S3), suggesting that they do not possess a Bor TOMM
cluster, or again, that the target genes are too divergent to
detect. The fact that the Bor TOMM is not present in the
13 Bbss published genomes [33] suggests that the former
is likely true for this species. Notably, Bbss has been re-
ported to produce a number of hemolytic factors [34, 35].
Mapping the distribution of a subset of the Bor
TOMM cluster data onto a maximum likelihood tree,
which was generated from a multilocus sequence typing
(MLST) analysis, further supports our hypothesis that
the Bor TOMM cluster has long been present in Borre-
lia (Additional file 9: Figure S5). The combined effects
of a non-exhaustive PCR screen with non-degenerate
primers and the unavoidable plasmid loss upon cultiva-
tion means that data reported here represent the mini-
mum distribution and prevalence of the Bor TOMM
cluster in Bbsl. However, these data demonstrate that
the newly-identified Bor TOMM cluster is underrepre-
sented in available genome sequences.
The SLS-like peptides from Borrelia are potential cytolysins
Given that cytolytic TOMM production has been impli-
cated in the virulence of some pathogens [7, 22, 18],
coupled with the prevalence of SLS-like TOMM clusters
in Bbsl, we decided to study the cytolytic potential of
one of the naturally C-terminally truncated SLS-like
peptides from Bbsl. In light of the complexity of Borrelia
cultivation requirements, the aforementioned tendency
to lose plasmids when cultured and inefficient genetic
tools [36, 37], we opted to take a reductionist approach
and assess the cytolytic potential of BvalA by heterol-
ogous expression in S. pyogenes ΔsagA. Importantly,
there is precedent for this approach, e.g. the SLS-like
precursor from C. botulinum (Fig. 1b) successfully com-
plemented S. pyogenes ΔsagA [7] and was later con-
firmed to function as a cytolysin in the context of a
native producer [17]. BvalA bears ~70 % amino acid
similarity to SagA (Fig. 5a) and the SagBCD proteins are
~50 % similar to their BvalBCD equivalents. However, no
hemolytic activity was observed upon heterologous ex-
pression of the non-cognate substrate BvalA in S. pyogenes
ΔsagA (Fig. 5b).
Substrate binding during TOMM biosynthesis occurs
via recognition of key motifs within N-terminal leader
region of the precursor peptide by the C-protein compo-
nent of the synthetase [25, 7]. Although partial binding
motifs appear to be present in the BorA leader peptides
(Fig. 5a), we cannot rule out the possibility that BvalA
was not bound by the S. pyogenes biosynthetic machin-
ery during heterologous expression. In light of this, we
generated a chimeric construct encoding the cognate
SagA leader peptide fused to the non-cognate BvalA
core peptide (SagA-BvalA; Fig. 5a). Such a strategy has
been exploited to replace highly divergent leader pep-
tides with the SagA leader to allow native interaction
with the heterocycle-forming synthetase [7]. In this way,
hemolytic activity was demonstrated for the SLS-like
core from S. aureus (Fig. 1b) upon expression in S. pyo-
genes ΔsagA [7]. However, SagA-BvalA was not hemolytic
under identical conditions (Fig. 5b). Co-expression of rare
streptococcal tRNAs [38] also failed to yield hemolysis
from BvalA or SagA-BvalA, suggesting that their inactivity
was not due to codon-usage bias during heterologous
expression.
Returning to the native SagA precursor peptide, we
noted a dramatic decrease in activity for SagA1–35 (which
could be considered a BvalA mimic; Fig. 5a), compared to
SagA1–36 (Fig. 2b). In case the hemolytic activity of SagA-
BvalA was just below the limit of detection of this assay,
we appended an alanine to the C-terminus of SagA-BvalA
(SagA-BvalA +A is akin to SagA1–36); however, hemolysis
was again not observed (Fig. 5b). While the SagA core
begins with a stretch of five contiguous cysteine resi-
dues, there is a serine residue at the fourth position of
the comparable region of BvalA (Fig. 5a). We thus cre-
ated SagA-BvalA-S27C, which partly rescued activity
(Fig. 5b), causing hemolysis only directly beneath the
colony compared to the zone of clearing observed in
strains with high hemolytic activity. Synthetase reac-
tions with reconstituted TOMM biosynthetic enzymes
have established that cysteine is cyclized more rapidly
than serine and threonine and several TOMM synthe-
tases are known to be selective for cysteine [39, 40].
We speculate that replacing serine with cysteine partly
ameliorates a bottleneck for SagBCD in processing an
unnatural substrate.
The lack of activity from BvalA-derived substrates upon
expression in S. pyogenes ΔsagA prompted us to assess
cytolytic potential using purified SagBCD enzymes. Previ-
ously, SLS-like cytolysins with no detectable activity when
Table 1 The Bor TOMM biosynthetic cluster is present among
diverse Bbsl isolates
PCR Positive
Bbsl species No. of strains screened borB borC borD All
Bbss 24 0 0 0 0
B. garinii 26 0 5 0 0
B. afzelii 47 26 34 19 14
B. spielmanii 7 5 5 5 5
B. bavariensis 13 0 0 0 0
B. valaisiana 21 3 15 3 3
B. lusitaniae 2 0 2 2 0
Positive PCR hits for Bor TOMM biosynthetic genes in Bbsl isolates. Strains
originated in Europe and Asia, except 11 Borrelia burgdorferi sensu stricto
(Bbss) from North America. “All” indicates the number of isolates testing
positive for genes encoding all three putative heterocycle forming enzymes,
BorBCD. More details are provided in Additional file 6: Table S3
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expressed in S. pyogenes ΔsagA were converted to cytoly-
sins by this approach [7]. Numerous factors contribute to
this, but perhaps most importantly, high concentrations of
reactants can be employed to increase the heterocycliza-
tion yield on non-optimal substrates. Additionally, this
cell-free system obviates the need for export/proteolysis
machinery to generate lytic entities [6, 7]. Attempts to ob-
tain sufficiently pure, full-length and active recombinant
BvalBCD were unsuccessful; however, after treatment with
the SagBCD homologs (Additional file 3: Table S1C),
BvalA and SagA-BvalA were both converted into cytoly-
sins with activity comparable to SagA and SagA1–35
(Fig. 5c). Omission of either the peptide substrate or
SagBCD resulted in no lysis, similar to the non-lytic C32A
mutant of SagA [7]. These data indicated that the BvalA
precursor peptide has the potential to be converted into a
cytolysin under certain conditions.
The majority of non-cognate and mutant precursor
peptides that become cytolytic upon treatment with
purified SagBCD were also lytic when constitutively
expressed in S. pyogenes ΔsagA [7]. However, there is
precedent for the failure of bona fide SLS-like precursors
to restore hemolysis in S. pyogenes ΔsagA, e.g. as was the
case with listeriolysin S (Fig. 1b) [18, 7]. The contrasting
results for BvalA and SagA-BvalA (Fig. 5b and c) are
reminiscent of the chimeric L. monocytogenes substrate,
SagA-LlsA, which was inactive in S. pyogenes ΔsagA but
was transformed into a cytolysin by purified SagBCD [7].
These results underscore the strict requirements for effi-
cient enzymatic processing and toxin export in S.
A
B C
Fig. 5 Hemolytic activity of SLS-like peptides expressed in S. pyogenes ΔsagA and modified by purified SagBCD enzymes. a Residues of the SagA
and SagA-BvalA precursors are numbered. The motifs known to be important for binding SagC [7] are shown in red for the SagA leader. Partial
binding motifs are also shown in red for the BvalA leader. Potentially modified residues are blue except C32, the position of a previously generated
alanine substitution that abolished cytolytic activity of SagA, which is marked in purple. The predicted leader cleavage sites are indicated with a caret.
The minimal core region required for hemolytic activity of SLS in S. pyogenes ΔsagA(SagA24–34) is underlined. The position of a stop codon introduced in
SagA to yield the SagA1–35 (BvalA mimic) is marked with an asterisk. SagA-BvalA-S27C and SagA-BvalA + A point mutants are represented by italicized
letters adjacent to the SagA-BvalA precursor sequence. The precursor peptide labels continue in panel B & C. b A representative colony on blood agar of
S. pyogenes ΔsagA expressing each precursor peptide from pDCerm is shown. The colony labeled “Empty” was a negative control containing pDCerm
vector. c Where appropriate, bars are labeled with + or – indicating presence or absence, respectively, of MBP-SagBCD in the reaction using the
indicated MBP-tagged precursor peptide. Triton X-100, positive control for 100 % lysis; PBS, negative control for background hemolysis. Error is reported
as the standard deviation of the mean (n = 3). * indicates P < 0.01 for each synthetase reaction versus the relevant unreacted precursor. P < 0.01 for all
lytic samples versus all negative controls, i.e. SagA-C32A reaction, enzymes alone (labeled SagB, SagC, SagD, and SagBCD), PBS
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pyogenes. Nevertheless, the ability of purified SagBCD to
convert BvalA into a cytolysin, coupled with the reten-
tion of activity by truncated SagA peptides upon func-
tional expression, suggests that the short SagA homologs
found in Bbsl may function as cytolysins in the context
of their native producers. However, whether this activity
is the primary function of the Bor TOMM (if produced)
requires additional study.
Conclusions
The results of our SagA truncation series indicate that, of
the 30 predicted to comprise the core peptide, the first 11
residues (SagA24–34) are sufficient for detectable hemolytic
activity of SLS when expressed in S. pyogenes ΔsagA. Thus,
our data indicates that the C-terminus of SagA is largely
dispensable and points to the NPH region as central to
SLS functionality, consistent with the conservation of this
motif in natural SLS variants as well as the greater TOMM
cytolysin family. Similar regions consisting of contiguous
heterocyclizable residues exist in the newly-described
SLS-like precursors encoded in multiple genera within Fir-
micutes, Spirochaetes and Actinobacteria. Although the
ability of BvalA and SagA1–35 to be matured into cytoly-
sins by purified SagBCD suggests that the “minimal cyto-
lytic unit” may be a general feature of TOMM cytolysins,
additional study will be required to determine if this holds
true for all family members, especially those with longer
stretches of heterocyclizable residues (e.g. listeriolysin S).
In order to comprehend our observation that much of the
hemolytic activity of SLS can be attributed to a mere 11
residues, a complete chemical structure of SLS and greater
molecular insight into the interaction of SLS with the cel-
lular membrane will be required.
Our identification of novel SLS-like biosynthetic clusters
greatly expands the TOMM cytolysin family. Of particular
interest is our discovery that many pathogenic Bbsl harbor the
genetic capacity to produce naturally truncated SLS-like
toxins. Although confirmation is needed, the most probable
function for the SLS-like biosynthetic clusters in Bbsl is to
generate a cytolytic factor, akin to the virulence-enhancing
SLS of S. pyogenes. Thus, the hypothetical “borreliolysin S”
toxin we identify herein warrants further investigation as it
would represent, to the best of our knowledge, the first post-
translationally modified natural product from any Spirochaete.
In summary, this work provides evidence that the core
NPH motif represents the defining feature of the SLS-
like TOMM family, as well as providing a foundation for
studies of the potential utilization of cytolytic TOMMs
by the diverse organisms described herein.
Methods
Bacterial culture conditions
Strains and plasmids used in this study are listed in
Additional file 10: Table S5, except Bbsl strains which
are listed in Additional file 6: Table S3. S. pyogenes were
grown at 37 °C in Todd–Hewitt broth or agar plates, or
on plates of 5 % sheep blood in tryptic soy agar (Hardy
Diagnostics) when determining hemolytic activity by func-
tional expression. For antibiotic selection, 5 μg ml−1
erythromycin was used. E. coli strains were grown at 37 °C
with aeration in Luria–Bertani broth or on Luria–Bertani
agar plates; antibiotic selection utilized 500 μg ml−1
erythromycin and 50 μg ml−1 kanamycin where relevant.
Genome mining for novel SLS-like clusters
The majority of TOMM clusters encode a precursor
peptide adjacent to SagB, −C and -D homologs [8, 10],
enabling their bioinformatic detection. Thus, novel SLS-
like clusters were identified by BLAST-P of known SLS-
like D proteins (SagD and homologs from C. botulinum, S.
aureus, L. monocytogenes) as the query sequence. After
identification of BvalD, BmurD, LactD, and EnduD, these
sequences were used as a query sequence to find other
homologs, with a BLAST e-value of 1e-30 as a cutoff. Sub-
sequently, homologs of other sag genes were identified in
the local genomic region of a single representative cluster
from each genus. Manual searches were performed in the
intergenic regions of the representative clusters for short,
unannotated genes encoding recognizable TOMM precur-
sors, which are usually overlooked by gene-identification
algorithms. Because of inherent duplications in RefSeq,
only a single representative sequence was used from
organisms with no strain information. Genome clusters
with low e-values were annotated manually for precur-
sor peptides and genomic regions that resembled known
cytolysins.
Maximum likelihood phylogenetic analysis
The D proteins of a diverse set of putative TOMM cy-
tolysin producers were analyzed because it is known
that the B and C proteins can sometimes be omitted
from TOMM biosynthetic gene clusters, whereas D
proteins are always present [10]. Further, the B and C
proteins are homologous to non-TOMM dehydroge-
nases and the E1-ubiquitin activating family of en-
zymes, and thus are prone to bioinformatic false-
positives. Thus, a D protein alignment was created
using the standard parameters of ClustalW [41] and
then a maximum likelihood tree was made using the
standard parameters of Molecular Evolutionary Genetics
Analysis (MEGA) [42]. MLST phylogenetic analysis was
generated in MEGA 5.1 using concatenated sequences of
eight chromosomally-located housekeeping genes (clpA,
clpX, nifS, pepX, pyrG, recG, rplB, and uvrA) [43] using
the maximum likelihood method with 1,000 bootstrap
repeats, the GTR model, uniform rates among sites and
nearest-neighbor-interchange.
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PCR screen for Bor TOMM biosynthetic genes
Genomic DNA of cultured Bbsl isolates was purified
using either a Qiagen DNeasy blood and tissue kit or a
High Pure PCR Template Preparation Kit (Roche Diag-
nostics) [44, 45]. Total DNA from field-collected quest-
ing ticks was extracted using alkaline hydrolysis [46].
Genomic DNA from each Bbsl isolate was tested for the
presence of borB, −C, and -D by Taq PCR with primers
specific to VS116 (Additional file 8: Table S4). Amplifi-
cation of a product of appropriate length as determined
by agarose gel electrophoresis was considered a positive
hit. Sanger sequencing confirmed the identity of PCR
amplicons from each species. Primers that effectively
amplified Bbsl 16S rRNA gene sequences were used to
verify that sufficient DNA was present in all samples.
Preparation of plasmids for S. pyogenes transformation
The chemically synthesized genes (Integrated DNA
Technologies) encoding BvalA and SagA-BvalA were
subcloned into pDCerm as previously described [7]. Stop
codons were introduced by site-directed mutagenesis.
Mutant candidates were miniprepped and verified by DNA
sequencing using pDCerm_
SeqMCS_F. Primers are listed in Additional file 8:
Table S4. In order to obtain sufficient plasmid DNA
for transformation of S. pyogenes ΔsagA, each pDCerm
construct was maxiprepped using an E.Z.N.A. Plasmid
Maxi Kit (Omega Bio-tek).
S. pyogenes transformation
S. pyogenes ΔsagA [22] was rendered electrocompetent
using a modified version of a previously published method
[47]. Briefly, S. pyogenes ΔsagA was grown to an OD600 of
0.35 in 50 ml Todd–Hewitt broth with 0.6 % (w/v) glycine.
Cells were washed three times with cold 0.625 M sucrose
(pH 4) and resuspended in 300 μl of the same buffer with
20 % (v/v) glycerol. 50 μl of cells was equilibrated with
~1 μg of plasmid DNA on ice for 30 min and electropo-
rated at 1.65 kV with a BioRad Micropulser. Immediately,
cells were added to 250 μl Todd–Hewitt broth with 0.25 M
sucrose and recovered for 2 h at 37 °C, before plating. The
S. pyogenes-nature of transformants [48] and presence of
pDCerm were verified by PCR (Additional file 8: Table S4).
Reaction of SLS-like peptides with purified SagBCD
All proteins were expressed with maltose-binding pro-
tein (MBP) fused to the N-terminus. SagA, SagA-C32A
[7], SagB, SagC and SagD were prepared as previously
described [6]. The genes encoding BvalA and SagA-
BvalA were subcloned into pET28b-MBP as previously
described [6]. Site-directed mutagenesis was performed
to yield pET28b-MBP-SagA1–35 (Additional file 8: Table
S4). Precursor peptides were expressed from E. coli
BL21(DE3)-RIPL (Stratagene) for 1 h at 30 °C after
induction with 1 mM IPTG at OD600 of 0.6. Following
standard lysis procedures, each protein was purified by
amylose affinity chromatography [6]. MBP-SagB, -C and
-D (10 μM each) were combined with the relevant MBP-
tagged precursor peptide (40 μM) and allowed to react in
synthetase buffer as previously described [6]. The products
of the synthetase reactions were applied to washed eryth-
rocytes and lysis assessed as previously described [6].
Hemoglobin absorbance was measured at 410 nm on a
Tecan Infinite® 200 PRO plate reader. Values were normal-
ized to a Triton X-100 positive control. Phosphate buff-
ered saline (PBS) served as a negative control.
Availability of supporting data
The data sets supporting the results of this article are
available in the Dryad Digital Repository (http://datadryad.
org/), doi:10.5061/dryad.d4863.
Additional files
Additional file 1: Figure S1. Alignment of experimentally validated
streptococcal SLS variants and SLS structure-activity relationships. (A)
Alignment using Clustal Omega [49] reveals that the SLS core region
possesses a highly conserved N-terminus containing 9–10 contiguous
heterocylizable residues (underlined), while the C-terminus is variable in
terms of both identity of residues and length. This phylogenetic data is
deposited in the Dryad Digital Repository, doi:10.5061/dryad.d4863. The
putative leader peptide cleavage sites are shown as carets. Residues of
SagA from S. pyogenes are numbered. C-terminal residues where alanine
substitutions were previously installed and that are specifically referred to
in the article are marked in red (see panel B). (B) Summary of cytolytic
activity of SagA core peptide mutants measured by expression in S.
pyogenes ΔsagA. Activity on blood agar equal to complementation with
wild-type SagA is designated as +++, 30–70 % activity is ++, less than
30 % activity is +, and non-detectable activity is –. C-terminal mutations
specifically referred to in the article are marked in red. Mutants were
expressed from pDCerm under control of a constitutive promoter [7] or
from pAD under control of the native sagA promoter [22].
Additional file 2: Figure S2. Gene cluster organization and precursor
peptide sequences of predicted SLS-like TOMM biosynthetic gene
clusters. (A) One example is given for each genus with strain abbreviations
as per Additional file 3: Table S1A. Lettering corresponds to the SLS operon
“sag” genes. The proposed function of each gene is color-coded according
to the legend. In the case of Lactococcus and Catelliglobosispora (included in
Fig. 3), the protein sequences are not associated with a genome in GenBank,
making it difficult to confirm all surrounding genes; thus, a representative
cluster organization was not given. Those clusters identified in Borrelia are
depicted in Fig. 4 and Additional file 5: Figure S3. (B) Potentially modified
residues are shown in blue. The predicted leader cleavage sites are indicated
with a caret.
Additional file 3: Table S1. Accession numbers and expectation values
of BCD proteins from representative SLS-like TOMM clusters. (A) Strains
used for the similarity analysis and the corresponding abbreviations
(continued in panels B and C). (B) GenBank accession numbers (ncbi.nlm.
nih.gov) of the B, C and D proteins used for the analysis. (C) BLAST e-values
for the designated proteins upon comparison with the B. valaisiana VS116
homolog. E-values were determined using BLAST-P with standard settings
and limiting the searched organisms to include only the strains in panel A,
except B. valaisiana VS116.
Additional file 4: Table S2. List of accession identifiers for D proteins
of putative TOMM cytolysin clusters. The genus, species, strain, and
GenBank accession identifiers are given for all D proteins used in the
phylogenetic analysis (Fig. 3), with inherent duplications from GenBank
RefSeq annotations deleted.
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Additional file 5: Figure S3. Open reading frame (ORF) diagrams for
Borrelia lp28-8 plasmids. Four published Bbsl genomes harbor plasmids
in the lp28-8 compatibility group [50]. As is is typical for Bbsl linear
plasmids [51], the lp28-8 plasmids are mosaically related; gray areas
between maps denote regions of sequence similarity. Lp28-8 from B.
burgdorferi 94a lacks the Bor TOMM biosynthetic cluster so is not
further discussed. The ORFs of the Bor TOMM clusters of B. spielmanii
A14S, B. valaisiana VS116 and B. afzelii PKo are color-coded as in Fig. 1A;
white arrows are hypothetical or have functions unrelated to the Bor
TOMM biosynthetic cluster. The numbers above an ORF give the Pfam
designation. Names of the ORFs known from type strain B. burgdorferi
B31 are labeled “b31_” and are shown below the maps. Each lp28-8
carries a truncated vls cassette region, which allows alteration of the
antigenic properties of VlsE outer surface proteins, a key pathogenic
strategy. An “X” over an ORF indicates a pseudogene. In VS116, the ABC
transporter gene has a substantial deletion and may be nonfunctional,
suggesting that a different transporter performs export or that VS116 does
not produce the Bor TOMM.
Additional file 6: Table S3. PCR screen for Bor TOMM biosynthetic
genes. These results provide more detail on those given in Table 1.
Strains marked in gray have published genomes. P# indicates number of
passages where known. Male (M), female (F) or nymph (N) is indicated
for tick isolates where known. In the case of human isolates, CSF
indicates isolation from cerebrospinal fluid. Disease presentation is given
where known: EM, erythema migrans; LD, Lyme disease; NB,
neuroborreliosis; ACA, acrodermatitis chronica atrophicans. Source
abbreviations: IP, Institute Pasteur; VF, Volker Fingerle; IS, Ira Schwartz; SC,
Sherwood Casjens; RM, Richard Marconi; AS, Arno Schönberg; GM:
Gabriele Margos; SB, Sven Bergstrom; PR, Patricia Rosa; UM, Ulrike
Munderloh; FS, Franc Strle; AvD, Alje van Dam. 1LGL Bayern, Germany.
*Bbsl species group currently contains 21 confirmed and proposed
species, including human pathogens, suspected pathogens and
non-pathogenic species [52–54]. aThe reported B. afzelii ACA-1 genome
sequence does not contain Bor TOMM genes [27]; however, we detected
borBCD in two of three ACA-1 strains of differing passage numbers.
Presumably lp28-8 was present in the original ACA-1 isolate but was lost
prior to the sequencing of its genome. This hypothesis is supported by a
report of the sequence of ACA-1 vls cassette region, also missing from
the published ACA-1 genome, indicating the presence of the lp28-8 in
their culture [55]. bBorBCD were not detected in passage 7 of a PKo strain
that at passage 6 had its genome sequenced [27]. In contrast, borBCD
were detected in another isolate of PKo at passage 10, again highlighting
the well-known heterogeneous nature of Bbsl upon cultivation.
Additional file 7: Figure S4. Nucleotide alignments of Bor TOMM
biosynthetic genes. BorB (A), borC (B) and borD (C) from Borrelia afzelii
PKo (Bafz), B. spielmanii A14S (Bspi), and B. valaisiana VS116 (Bval) were
aligned using ClustalW. This phylogenetic data is deposited in the Dryad
Digital Repository, doi:10.5061/dryad.d4863. Sites where PCR screening
primers annealed are underlined. The primers used to detect borB/C/D
(Table 1 and Additional file 6: Table S3) were based on bvalB/C/D from B.
valaisiana VS116 (Additional file 8: Table S4). The number of mismatches
per primer when compared to the two other sequenced examples of the
gene is indicated in parentheses for each.
Additional file 8: Table S4. Primers used in this study. In all cases, bvalA/
B/C/D or BvalA/B/C/D refers to the relevant TOMM genes or proteins from B.
valaisiana VS116. Restriction endonuclease recognition sites are underlined.
Lower-case letters indicate bases targeted for mutagenesis.
Additional file 9: Figure S5. Maximum likelihood tree of Bbsl strains
used in the Bor TOMM PCR screen. The tree shows the relationships of a
number of Borrelia strains, including a subset of the Bbsl strains included
in our PCR screen. This phylogenetic data is deposited in the Dryad
Digital Repository, doi:10.5061/dryad.d4863. A plus sign (+) next to the
strain designation indicates that gene(s) from the Bor TOMM biosynthetic
cluster (borB/borC/borD) was/were detected (Additional file 6: Table S3).
WGS: whole genome sequence.
Additional file 10: Table S5. Strains and plasmids used in this study. In
all cases, bvalA/BvalA refers to the TOMM gene/peptide from B. valaisiana
VS116. The sequences of the relevant precursor peptides are shown in
Figs. 2A and 5A.
Abbreviations
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